Doctor Urges Individualized Hormone Therapy for 4 Million U.S. Breast Cancer Survivors
Updated
Updated · Oprah Mag · Jul 21
Doctor Urges Individualized Hormone Therapy for 4 Million U.S. Breast Cancer Survivors
2 articles · Updated · Oprah Mag · Jul 21
Summary
More than 4 million U.S. breast cancer survivors are being denied hormone therapy under a blanket ban that Kelly Casperson says should be replaced with individualized risk-benefit discussions.
2025 FDA action removing the black-box warning from vaginal estrogen is cited as evidence that newer data support some hormone treatments as safe and effective for menopause symptoms.
The case against systemic hormone therapy rests heavily on the early HABITS trial, but Casperson argues its lack of mandatory mammograms and use of older synthetic progestins limit its relevance today.
The Stockholm trial, which restricted progestin exposure, found no difference in new breast cancer cases after 4.1 and 10.8 years, reinforcing her argument that hormone type and dose matter.
With five-year relative breast cancer survival near 92%, Casperson says care should shift toward quality of life, using cancer type, recurrence risk and symptom burden to guide treatment choices.